Obstet Gynecol Sci.  2017 Jul;60(4):350-356. 10.5468/ogs.2017.60.4.350.

Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma

• Kim HJ
• Lee HM
• Kim MK
• Lee YK
• Lee IH
• Lee KH
• Kim H

• KMID: 2386276
• DOI: http://doi.org/10.5468/ogs.2017.60.4.350

Abstract

OBJECTIVE
Ovarian carcinosarcoma is a rare subtype of this disease that has not been thoroughly investigated. The aim of this study was to evaluate the prognostic factors and out comes in patients with ovarian carcinosarcoma.
METHODS
All patients with histologically confirmed ovarian carcinosarcoma who were treated at Cheil General Hospital and Women's Healthcare Center between January 2000 and December 2015 were identified and analyzed. Data were extracted from medical records, and statistical analyses were performed to determine correlations between clinicopathological parameters and survival outcomes.
RESULTS
Of the 822 patients diagnosed with ovarian cancer over 16 years, 11 (1.3%) had ovarian carcinosarcoma histology. Every patient underwent surgery as the initial treatment followed by intravenous adjuvant chemotherapy. Only 18.1% of cases were early stage (I or II) while 81.8% were advanced stage (III or IV) according to the FIGO (International Federation of Gynecology and Obstetrics) classification. Six cases were of the homologous subtype (54.5%) and five were of the heterologous subtype (45.5%). There was no significant difference in survival according to stage (P=0.24). The heterologous subtype and residual disease were associated with poor disease-free survival (P=0.02 and P=0.04) and overall survival (P=0.02 and P=0.04), On multivariate analysis, the histological subtype was an independent prognostic factor (P=0.02).
CONCLUSION
Optimal cytoreduction without gross residual disease and a homologous subtype are favorable prognostic factors in terms of disease relapse and survival.

Keyword

Carcinosarcoma; Histology; Ovarian neoplasms; Prognosis

MeSH Terms

Carcinosarcoma*
Chemotherapy, Adjuvant
Classification
Delivery of Health Care
Disease-Free Survival
Gynecology
Hospitals, General
Humans
Medical Records
Multivariate Analysis
Ovarian Neoplasms
Prognosis
Recurrence

Figure

• 

  Fig. 1 Kaplan-Meier survival curves according to the histopathological subtype. (A) Disease-free survival and (B) overall survival.

• 

  Fig. 2 Kaplan-Meier survival curves according to the presence of a residual mass. (A) Disease-free survival and (B) overall survival.

Reference

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–E386.

2. Silasi DA, Illuzzi JL, Kelly MG, Rutherford TJ, Mor G, Azodi M, et al. Carcinosarcoma of the ovary. Int J Gynecol Cancer. 2008; 18:22–29.

3. George EM, Herzog TJ, Neugut AI, Lu YS, Burke WM, Lewin SN, et al. Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. Gynecol Oncol. 2013; 131:42–45.

4. Jin Z, Ogata S, Tamura G, Katayama Y, Fukase M, Yajima M, et al. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol. 2003; 22:368–373.

5. Harris MA, Delap LM, Sengupta PS, Wilkinson PM, Welch RS, Swindell R, et al. Carcinosarcoma of the ovary. Br J Cancer. 2003; 88:654–657.

6. Rauh-Hain JA, Diver EJ, Clemmer JT, Bradford LS, Clark RM, Growdon WB, et al. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol. 2013; 131:46–51.

7. Iwase H, Takada T, Iitsuka C, Nomura H, Abe A, Taniguchi T, et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. J Gynecol Oncol. 2015; 26:303–310.

8. Bicher A, Levenback C, Silva EG, Burke TW, Morris M, Gershenson DM. Ovarian malignant mixed mullerian tumors treated with platinum-based chemotherapy. Obstet Gynecol. 1995; 85:735–739.

9. Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer. 2004; 100:2148–2153.

10. Morrow CP, d'Ablaing G, Brady LW, Blessing JA, Hreshchyshyn MM. A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: a Gynecologic Oncology Group study. Gynecol Oncol. 1984; 18:278–292.

11. Chang J, Sharpe JC, A'Hern RP, Fisher C, Blake P, Shepherd J, et al. Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Ann Oncol. 1995; 6:755–758.

12. Muller M, Dupre PF, Lucas B, Simon H, Malhaire JP, Guillemet C, et al. Carcinosarcoma of the ovary. J Gynecol Obstet Biol Reprod (Paris). 2007; 36:399–402.

13. Rauh-Hain JA, Growdon WB, Rodriguez N, Goodman AK, Boruta DM 2nd, Schorge JO, et al. Carcinosarcoma of the ovary: a case-control study. Gynecol Oncol. 2011; 121:477–481.

14. Loizzi V, Cormio G, Camporeale A, Falagario M, De Mitri P, Scardigno D, et al. Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature. Oncology. 2011; 80:102–106.

15. Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, et al. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer. 1998; 82:1731–1737.

16. Mok JE, Kim YM, Jung MH, Kim KR, Kim DY, Kim JH, et al. Malignant mixed Mullerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer. 2006; 16:101–105.

17. Amant F, Vloeberghs V, Woestenborghs H, Moerman P, Vergote I. Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecol Oncol. 2003; 90:372–377.

18. Leiser AL, Chi DS, Ishill NM, Tew WP. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol. 2007; 105:657–661.

19. Muntz HG, Jones MA, Goff BA, Fuller AF Jr, Nikrui N, Rice LW, et al. Malignant mixed mullerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy. Cancer. 1995; 76:1209–1213.